1 Targeted Drugs for Multiple Myeloma Market Overview
1.1 Product Overview and Scope of Targeted Drugs for Multiple Myeloma
1.2 Classification of Targeted Drugs for Multiple Myeloma by Types
1.2.1 Global Targeted Drugs for Multiple Myeloma Revenue Comparison by Types (2020-2025)
1.2.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Types in 2018
1.2.3 Immunomodulator
1.2.4 Proteasome Inhibitors
1.2.5 Histone Deacetylase Inhibitors (HDACI)
1.2.6 Monoclonal Antibody
1.2.7 Other
1.3 Global Targeted Drugs for Multiple Myeloma Market by Application
1.3.1 Global Targeted Drugs for Multiple Myeloma Market Size and Market Share Comparison by Applications (2015-2025)
1.3.2 Hospital
1.3.3 Drug Center
1.3.4 Clinic
1.3.5 Other
1.4 Global Targeted Drugs for Multiple Myeloma Market by Regions
1.4.1 Global Targeted Drugs for Multiple Myeloma Market Size (Million USD) Comparison by Regions (2015-2025)
1.4.1 North America (USA, Canada and Mexico) Targeted Drugs for Multiple Myeloma Status and Prospect (2015-2025)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drugs for Multiple Myeloma Status and Prospect (2015-2025)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drugs for Multiple Myeloma Status and Prospect (2015-2025)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drugs for Multiple Myeloma Status and Prospect (2015-2025)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drugs for Multiple Myeloma Status and Prospect (2015-2025)
1.5 Global Market Size of Targeted Drugs for Multiple Myeloma (2015-2025)
2 Manufacturers Profiles
2.1 Celgene
2.1.1 Business Overview
2.1.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Celgene Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.2 SL Pharma
2.2.1 Business Overview
2.2.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 SL Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.3 Natco Pharma
2.3.1 Business Overview
2.3.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.4 Intas Pharmaceuticals
2.4.1 Business Overview
2.4.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.5 Indiabulls Pharmaceutical
2.5.1 Business Overview
2.5.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.6 Cipla
2.6.1 Business Overview
2.6.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Cipla Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.7 Glenmark Pharmaceuticals
2.7.1 Business Overview
2.7.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.8 Dr Reddy\'s Laboratories
2.8.1 Business Overview
2.8.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Dr Reddy\'s Laboratories Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.9 Qilu Pharmaceutical
2.9.1 Business Overview
2.9.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.10 Chia Tai-Tianqing
2.10.1 Business Overview
2.10.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.11 Hanson Pharm
2.11.1 Business Overview
2.11.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.12 Meidakang Huakang Pharmaceutical
2.12.1 Business Overview
2.12.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.13 Shandong Kongfu Pharmaceutical
2.13.1 Business Overview
2.13.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.14 J&J
2.14.1 Business Overview
2.14.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 J&J Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.15 Takeda
2.15.1 Business Overview
2.15.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Takeda Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.16 Amgen
2.16.1 Business Overview
2.16.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Amgen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.17 Bristol Myers Squibb
2.17.1 Business Overview
2.17.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.18 Abbvie
2.18.1 Business Overview
2.18.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Abbvie Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.19 Seattle Genetics
2.19.1 Business Overview
2.19.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.20 Karyopharm Therapeutics
2.20.1 Business Overview
2.20.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.21 PDL BioPharma
2.21.1 Business Overview
2.2.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.22 Roche
2.22.1 Business Overview
2.22.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Roche Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.23 Sumitomo
2.23.1 Business Overview
2.23.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.24 Merck
2.24.1 Business Overview
2.24.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 Merck Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.25 Biogen
2.25.1 Business Overview
2.25.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Biogen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.26 Schering-Plough
2.26.1 Business Overview
2.26.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.26.2.1 Product A
2.26.2.2 Product B
2.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.27 Glaxo
2.27.1 Business Overview
2.27.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.27.2.1 Product A
2.27.2.2 Product B
2.27.3 Glaxo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
2.28 Chiron
2.28.1 Business Overview
2.28.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.28.2.1 Product A
2.28.2.2 Product B
2.28.3 Chiron Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
3 Global Targeted Drugs for Multiple Myeloma Market Competition, by Players
3.1 Global Targeted Drugs for Multiple Myeloma Revenue and Share by Players (2015-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drugs for Multiple Myeloma Players Market Share
3.2.2 Top 10 Targeted Drugs for Multiple Myeloma Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drugs for Multiple Myeloma Market Size by Regions
4.1 Global Targeted Drugs for Multiple Myeloma Revenue and Market Share by Regions
4.2 North America Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
4.3 Europe Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
4.4 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
4.5 South America Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
4.6 Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
5 North America Targeted Drugs for Multiple Myeloma Revenue by Countries
5.1 North America Targeted Drugs for Multiple Myeloma Revenue by Countries (2015-2019)
5.2 USA Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
5.3 Canada Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
5.4 Mexico Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
6 Europe Targeted Drugs for Multiple Myeloma Revenue by Countries
6.1 Europe Targeted Drugs for Multiple Myeloma Revenue by Countries (2015-2019)
6.2 Germany Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
6.3 UK Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
6.4 France Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
6.5 Russia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
6.6 Italy Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
7 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Countries
7.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Countries (2015-2019)
7.2 China Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
7.3 Japan Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
7.4 Korea Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
7.5 India Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
7.6 Southeast Asia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
8 South America Targeted Drugs for Multiple Myeloma Revenue by Countries
8.1 South America Targeted Drugs for Multiple Myeloma Revenue by Countries (2015-2019)
8.2 Brazil Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
8.3 Argentina Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
8.4 Colombia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
9 Middle East and Africa Revenue Targeted Drugs for Multiple Myeloma by Countries
9.1 Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue by Countries (2015-2019)
9.2 Saudi Arabia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
9.3 UAE Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
9.4 Egypt Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
9.5 Nigeria Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
9.6 South Africa Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2015-2019)
10 Global Targeted Drugs for Multiple Myeloma Market Segment by Type
10.1 Global Targeted Drugs for Multiple Myeloma Revenue and Market Share by Type (2015-2019)
10.2 Global Targeted Drugs for Multiple Myeloma Market Forecast by Type (2020-2025)
10.3 Immunomodulator Revenue Growth Rate (2015-2025)
10.4 Proteasome Inhibitors Revenue Growth Rate (2015-2025)
10.5 Histone Deacetylase Inhibitors (HDACI) Revenue Growth Rate (2015-2025)
10.6 Monoclonal Antibody Revenue Growth Rate (2015-2025)
10.7 Other Revenue Growth Rate (2015-2025)
11 Global Targeted Drugs for Multiple Myeloma Market Segment by Application
11.1 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Application (2015-2019)
11.2 Targeted Drugs for Multiple Myeloma Market Forecast by Application (2020-2025)
11.3 Hospital Revenue Growth (2015-2019)
11.4 Drug Center Revenue Growth (2015-2019)
11.5 Clinic Revenue Growth (2015-2019)
11.6 Other Revenue Growth (2015-2019)
12 Global Targeted Drugs for Multiple Myeloma Market Size Forecast (2020-2025)
12.1 Global Targeted Drugs for Multiple Myeloma Market Size Forecast (2020-2025)
12.2 Global Targeted Drugs for Multiple Myeloma Market Forecast by Regions (2020-2025)
12.3 North America Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2020-2025)
12.4 Europe Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2020-2025)
12.5 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2020-2025)
12.6 South America Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2020-2025)
12.7 Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2020-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
